Back to Search Start Over

Raloxifene Prevents Chemically-Induced Ferroptotic Neuronal Death In Vitro and In Vivo.

Authors :
Hao X
Wang Y
Hou MJ
Liao L
Yang YX
Wang YH
Zhu BT
Source :
Molecular neurobiology [Mol Neurobiol] 2025 Mar; Vol. 62 (3), pp. 3934-3955. Date of Electronic Publication: 2024 Oct 02.
Publication Year :
2025

Abstract

Ferroptosis, a regulated form of cell death characterized by excessive iron-dependent lipid peroxidation, can be readily induced in cultured cells by chemicals such as erastin and RSL3. Protein disulfide isomerase (PDI) has been identified as an upstream mediator of chemically induced ferroptosis and also a target for ferroptosis protection. In this study, we discovered that raloxifene (RAL), a selective estrogen receptor modulator known for its neuroprotective actions in humans, can effectively inhibit PDI function and provide robust protection against chemically induced ferroptosis in cultured HT22 neuronal cells. Specifically, RAL can bind directly to PDI both in vitro and in intact neuronal cells and inhibit its catalytic activity. Computational modeling analysis reveals that RAL can tightly bind to PDI through forming a hydrogen bond with its His256 residue, and biochemical analysis further shows that when PDI's His256 is mutated to Ala256, RAL loses its inhibition of PDI's catalytic activity. This inhibition of PDI by RAL significantly reduces the dimerization of both the inducible and neuronal nitric oxide synthases and the accumulation of nitric oxide, both of which have recently been shown to play a crucial role in mediating chemically induced ferroptosis through subsequent induction of ROS and lipid-ROS accumulation. In vivo behavioral analysis shows that mice treated with RAL are strongly protected against kainic acid-induced memory deficits and hippocampal neuronal damage. In conclusion, this study demonstrates that RAL is a potent inhibitor of PDI and can effectively prevent chemically induced ferroptosis in hippocampal neurons both in vitro and in vivo. These findings offer a novel estrogen receptor-independent mechanism for RAL's neuroprotective actions in animal models and humans.<br />Competing Interests: Declarations. Ethics Approval: The procedures of the animal experiments described in this study were approved by the Institutional Animal Care and Use Committee (IACUC) of The Chinese University of Hong Kong (Shenzhen) (approval date: October 28, 2021; protocol #: CUHKSZ-AE2021002). Consent to Participate: Not applicable. Consent to Publication: Not applicable. Competing Interests: The authors declare no competing interests.<br /> (© 2024. The Author(s).)

Details

Language :
English
ISSN :
1559-1182
Volume :
62
Issue :
3
Database :
MEDLINE
Journal :
Molecular neurobiology
Publication Type :
Academic Journal
Accession number :
39354232
Full Text :
https://doi.org/10.1007/s12035-024-04497-7